Watch SGMT. Know when insiders buy.
One email the day a filing lands. Free.
SGMT
Sagimet Biosciences Inc.
9.36
+0.13 +1.35%
USD · close Sep 28
A free account adds a watchlist, alerts when insiders, Congress or short sellers move on your tickers, and a morning brief. Sign up
Work order
90
PASS · shorts 90
Insiders, 90 days
0
no open-market filings in 90 days
Congress, 90 days
0 / 0
no disclosures naming it
Big money
0 / 15
none of the tracked funds disclose it
Calls on record
0
nobody we score has called it yet
MKT CAP $287.3MP/E —DIV YIELD —FCF YIELD —REV TTM —NET INCOME −$47.1MNET CASH —52W 4.55 – 11.17SEC XBRL · TTM TO Invalid Date
Financials
By quarter
| Period | Revenue | YoY | Gross margin | Operating income | Net income | YoY | EPS | Op. cash flow | Capex | Free cash flow | Filed |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Q2 2026 · Jun 30 | — | — | — | −$15.8M | −$14M | — | -0.26 | −$11.1M | — | — | Aug 11 |
| Q1 2026 · Mar 31 | — | — | — | −$11.7M | −$10.7M | — | -0.33 | −$8.6M | — | — | Aug 11 |
| Q4 2025 · Dec 31derived | — | — | — | −$10.8M | −$9.6M | — | -0.30 | −$11.8M | — | — | Mar 11 |
| Q3 2025 · Sep 30 | — | — | — | −$14.3M | −$12.9M | — | -0.40 | −$10.2M | — | — | Nov 13 |
| Q2 2025 · Jun 30 | — | — | — | −$11.9M | −$10.4M | — | -0.32 | −$9.1M | — | — | Aug 11 |
| Q1 2025 · Mar 31 | — | — | — | −$19.9M | −$18.2M | — | -0.56 | −$14.5M | — | — | Aug 11 |
| Q4 2024 · Dec 31derived | — | — | — | −$18.2M | −$16.2M | — | -0.50 | −$11M | — | — | Mar 11 |
| Q3 2024 · Sep 30 | — | — | — | −$16.9M | −$14.6M | — | -0.45 | −$19.6M | — | — | Nov 13 |
| Q2 2024 · Jun 30 | — | — | — | −$10.6M | −$8.1M | — | -0.25 | −$5.6M | — | — | Nov 13 |
| Q1 2024 · Mar 31 | — | — | — | −$8.8M | −$6.6M | — | -0.23 | −$6.2M | — | — | Nov 13 |
| Q4 2023 · Dec 31derived | $0 | — | — | −$9.5M | −$8.2M | — | 0.56 | −$7.1M | — | — | Mar 12 |
| Q3 2023 · Sep 30 | $2M | — | — | −$7.5M | −$6.4M | — | -0.35 | −$3.9M | — | — | Nov 14 |
By fiscal year
| Year | Revenue | Gross margin | Operating income | Net income | Net margin | EPS | Op. cash flow | Capex | Free cash flow | Buybacks | Dividends paid |
|---|---|---|---|---|---|---|---|---|---|---|---|
| FY2025 · to Dec 31 | — | — | −$56.9M | −$51M | — | -1.58 | −$45.6M | — | — | — | — |
| FY2024 · to Dec 31 | — | — | −$54.5M | −$45.6M | — | -1.45 | −$42.4M | — | — | — | — |
| FY2023 · to Dec 31 | $2M | — | −$30.7M | −$27.9M | -1393.8% | -2.66 | −$23.8M | — | — | — | — |
| FY2022 · to Dec 31 | — | — | −$31.1M | −$30.5M | — | -165.20 | −$24.5M | — | — | — | — |
Every number comes from Sagimet Biosciences Inc.'s own XBRL-tagged filings with the SEC, not a data vendor. Quarters marked derived are the fiscal year minus the three reported quarters, the same way every data provider computes Q4. Restated figures replace originals as later filings arrive.